[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX360048B - Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico. - Google Patents

Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.

Info

Publication number
MX360048B
MX360048B MX2015009617A MX2015009617A MX360048B MX 360048 B MX360048 B MX 360048B MX 2015009617 A MX2015009617 A MX 2015009617A MX 2015009617 A MX2015009617 A MX 2015009617A MX 360048 B MX360048 B MX 360048B
Authority
MX
Mexico
Prior art keywords
crystalline forms
chlorophenoxy
cyano
carbonyl
hydroxy
Prior art date
Application number
MX2015009617A
Other languages
English (en)
Other versions
MX2015009617A (es
Inventor
Witschi Claudia
P Arend Michael
Min Park Jung
D Thompson Michael
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360048(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of MX2015009617A publication Critical patent/MX2015009617A/es
Publication of MX360048B publication Critical patent/MX360048B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidrox-soquinoIin-3-carbonil]-amino }- acético (Compuesto A), el proceso para preparar formas cristalinas de Compuesto A, las composiciones farmacéuticas que las contienen y los métodos de uso de las mismas.
MX2015009617A 2013-01-24 2014-01-23 Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico. MX360048B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361756361P 2013-01-24 2013-01-24
PCT/US2014/012780 WO2014116849A1 (en) 2013-01-24 2014-01-23 Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Publications (2)

Publication Number Publication Date
MX2015009617A MX2015009617A (es) 2016-04-20
MX360048B true MX360048B (es) 2018-10-19

Family

ID=50073508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009617A MX360048B (es) 2013-01-24 2014-01-23 Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.

Country Status (16)

Country Link
US (1) US9643928B2 (es)
EP (1) EP2951159B1 (es)
JP (1) JP6437456B2 (es)
KR (1) KR102233081B1 (es)
CN (1) CN105452227B (es)
AU (1) AU2014209319B2 (es)
CA (1) CA2899024C (es)
DK (1) DK2951159T3 (es)
ES (1) ES2694297T3 (es)
HK (1) HK1217331A1 (es)
IL (1) IL240066B (es)
MX (1) MX360048B (es)
RU (1) RU2666144C2 (es)
SG (2) SG10202009266PA (es)
TW (1) TWI685487B (es)
WO (1) WO2014116849A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
NZ592741A (en) 2008-11-14 2013-03-28 Fibrogen Inc Thiochromene derivatives as hif hydroxylase inhibitors
NZ704662A (en) 2012-07-16 2017-07-28 Fibrogen Inc Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
CN106083719B (zh) 2012-07-16 2019-10-18 菲布罗根有限公司 制备异喹啉化合物的方法
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP2951159B1 (en) 2013-01-24 2018-08-22 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
PL3003284T3 (pl) 2013-06-06 2020-08-10 Fibrogen, Inc. Formulacje farmaceutyczne inhibitora 5 hydroksylazy hif
EP3190104B1 (en) 2014-09-02 2021-10-27 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0626178A1 (de) 1993-05-17 1994-11-30 Ciba-Geigy Ag Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
ATE149486T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
PT944619E (pt) 1996-11-27 2007-01-31 Bristol Myers Squibb Pharma Co Novos antagonistas dos receptores da integrina
GB9707830D0 (en) 1997-04-18 1997-06-04 Smithkline Beecham Plc Novel compounds
AU7526798A (en) 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
US6777425B2 (en) 2001-06-13 2004-08-17 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
WO2002101073A2 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
DK2289531T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc Medications for the treatment or prevention of anemia
GB0206711D0 (en) 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
JP2007523870A (ja) 2003-07-15 2007-08-23 メルク エンド カムパニー インコーポレーテッド ヒドロキシピリジンcgrp受容体拮抗薬
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
AU2004263508A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7248053B2 (en) 2004-07-15 2007-07-24 Powerprecise Solutions, Inc. One time operating state detecting method and apparatus
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
KR20080028918A (ko) 2005-06-15 2008-04-02 피브로겐, 인크. 암의 치료를 위한 화합물과 방법
EP2476669A1 (en) * 2006-01-27 2012-07-18 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
EP1991269A1 (en) * 2006-02-16 2008-11-19 Fibrogen, Inc. Compounds and methods for treatment of stroke
RU2461557C2 (ru) 2006-04-04 2012-09-20 Файброджен, Инк. Соединения пирроло- и тиазолопиридина (варианты) и фармацевтическая композиция на их основе
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
EP2231156A1 (en) * 2007-12-07 2010-09-29 Fibrogen, Inc. Methods for increasing white blood cells
EP2951159B1 (en) 2013-01-24 2018-08-22 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Also Published As

Publication number Publication date
IL240066A0 (en) 2015-09-24
HK1217331A1 (zh) 2017-01-06
CA2899024C (en) 2022-01-04
EP2951159B1 (en) 2018-08-22
SG11201505748UA (en) 2015-08-28
CN105452227B (zh) 2018-05-29
US20160002170A1 (en) 2016-01-07
KR102233081B1 (ko) 2021-03-29
AU2014209319A1 (en) 2015-08-27
EP2951159A1 (en) 2015-12-09
US9643928B2 (en) 2017-05-09
RU2015134420A (ru) 2017-03-03
CA2899024A1 (en) 2014-07-31
JP2016505071A (ja) 2016-02-18
TWI685487B (zh) 2020-02-21
SG10202009266PA (en) 2020-10-29
RU2666144C2 (ru) 2018-09-06
TW201444800A (zh) 2014-12-01
JP6437456B2 (ja) 2018-12-12
KR20150129679A (ko) 2015-11-20
ES2694297T3 (es) 2018-12-19
MX2015009617A (es) 2016-04-20
CN105452227A (zh) 2016-03-30
IL240066B (en) 2019-08-29
WO2014116849A1 (en) 2014-07-31
DK2951159T3 (en) 2018-11-19
AU2014209319B2 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
IN2015KN00262A (es)
MX2015009617A (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
MX2015000962A (es) COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(ß-D-GLU COPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS.
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MX2013000009A (es) Procedimiento de preparacion de la sal de l-arginina de perindoprilo.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
PH12016500577B1 (en) Piperazine derivatives and the use thereof as medicament
MX2016009667A (es) Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma.
IN2013CH04906A (es)
WO2014141294A3 (en) An improved process for the synthesis of melphalan and the hydrochloride salt
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
MX2015015746A (es) Proceso para la preparacion de arformoterol o sal del mismo.
IN2013MU04056A (es)
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
IN2013CH04314A (es)
IN2013MU03508A (es)
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
IN2014DE01203A (es)
IN2013CH04330A (es)
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
IN2014DN10683A (es)
MX2016005222A (es) Tinturas acidas, proceso para su produccion y su uso.
IN2013MU03610A (es)

Legal Events

Date Code Title Description
FG Grant or registration